Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Orthopediatrics Corp

Company price
31.61 USD 0.20 ( 0.64%)
Last update at 2026-11-18T20:54:00Z
VOLUME
112198
Market Cap
607.44M

Momentum Score

…

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
31.42
Low
32.73
High
52 Week Price Range
14.42
Low
26.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Orthopediatrics Corp supplies implants and surgical instruments for pediatric orthopedic conditions, focusing on trauma, deformity and spine in children. Its long-term growth may be supported by expanding product portfolio, geographic expansion and increasing adoption of specialized pediatric implants, and investors may find the company attractive because it occupies a narrow, specialty market with technical barriers to entry and procedure-driven demand.
Primary risks include sensitivity to surgical procedure volumes and reimbursement changes, regulatory and approval hurdles for new products, and competitive pressure from larger orthopedics companies.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
31.41
Dividend Yield
-
Revenue TTM
252.72M
Revenue Per Share
10.65
Gross Profit TTM
186.14M
Debt / Equity
0.29
ROE
-11.36%
Net Debt
80.43M
ROCE
-7.18%
Diluted EPS TTM
-1.68

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.19M -41.93M -21.31M -3.69M -17.39M
Net income -39.65M -37.82M -20.97M 1.26M -16.26M
Selling general administrative 119.83M 102.79M 73.30M 59.38M 46.06M
Selling and marketing expenses 72.73M 64.30M 52.82M 45.05M 39.67M
Gross profit 172.66M 148.60M 111.25M 90.66M 73.40M
Reconciled depreciation 21.12M 19.08M 15.72M 13.10M 10.68M
Ebit -33.19M -39.31M -25.77M -21.79M -17.87M
Ebitda -11.94M -20.23M -8.38M -10.49M -6.11M
Depreciation and amortization 21.25M 19.08M 17.39M 11.30M 11.76M
Non operating income net other - - - 24.13M 2.88M
Operating income -29.00M -29.52M -26.75M -21.79M -17.87M
Other operating expenses 265.35M 234.25M 175.48M 144.08M 115.92M
Interest expense 6.00M 2.62M 0.20M 2.42M 2.25M
Tax provision 0.46M -4.11M -0.17M -4.95M -1.13M
Net interest income -6.00M -2.62M -0.04M -2.42M -2.25M
Non recurring - - - 3.61M 0.15M
Income tax expense 0.46M -4.11M -0.34M -4.95M -1.13M
Total revenue 236.35M 204.73M 148.73M 122.29M 98.05M
Total operating expenses 201.66M 178.12M 138.00M 112.45M 91.28M
Cost of revenue 63.69M 56.13M 37.48M 31.63M 24.65M
Total other income expense net -10.19M -12.41M 5.44M 18.10M 0.49M
Net income from continuing ops -39.65M -37.82M -22.13M 1.26M -16.26M
Net income applicable to common shares - - - 1.26M -16.26M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 508.63M 473.21M 449.59M 427.73M 304.27M
Intangible assets 77.71M 81.18M 84.56M 79.90M 69.76M
Other current assets 7.94M 8.98M 3.75M 3.97M 4.59M
Total liab 162.03M 118.64M 72.56M 49.08M 78.91M
Total stockholder equity 346.60M 354.57M 377.02M 378.65M 225.37M
Other current liab 27.24M 22.77M 18.72M 13.62M 2.04M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -275.21M -235.56M -197.74M -176.77M -178.03M
Other liab - - - 17.19M 48.28M
Good will 109.27M 93.84M 83.70M 86.82M 72.35M
Cash 19.56M 43.82M 33.03M 8.99M 7.64M
Total current liabilities 46.20M 33.96M 41.67M 30.87M 29.71M
Current deferred revenue - - - 5.95M 18.21M
Net debt 80.43M 37.08M -9.27M -8.08M -6.60M
Short term debt 0.17M 2.28M 10.30M 0.14M 0.14M
Short long term debt 0.17M 0.16M 0.15M 0.14M 0.14M
Short long term debt total 99.99M 80.90M 23.76M 0.91M 1.04M
Other stockholder equity 622.33M 600.90M 580.29M 560.81M 394.90M
Property plant equipment - - - 34.29M 28.52M
Total current assets 256.42M 237.17M 226.50M 226.72M 133.65M
Net tangible assets - - - 211.93M 83.26M
Short term investments 41.30M 25.01M 49.25M 109.30M 45.90M
Net receivables 53.84M 42.36M 34.62M 24.80M 17.94M
Long term debt 99.82M 72.96M 9.91M 0.76M 0.91M
Inventory 133.79M 117.00M 105.85M 78.19M 57.57M
Accounts payable 18.79M 8.91M 12.65M 11.15M 9.32M
Accumulated other comprehensive income -0.52M -10.77M -5.53M -5.40M 8.49M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -176.77M -178.03M
Non currrent assets other 15.68M 24.99M 1.08M -5.95M 9.50M
Non current assets total 252.21M 236.04M 223.09M 201.01M 170.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -17.02M -13.16M 0.53M -63.25M 9.25M
Change to liabilities - - - 3.13M 0.53M
Total cashflows from investing activities -43.63M -13.16M 41.68M -113.37M -7.41M
Net borrowings 24.84M 61.15M 9.28M -3.37M -0.13M
Total cash from financing activities 23.98M 53.13M 7.30M 135.97M 0.01M
Change to operating activities - - - 3.37M -6.47M
Net income -39.65M -37.82M -20.97M 1.26M -16.26M
Change in cash -24.16M 12.75M 22.57M 1.46M -21.13M
Begin period cash flow 45.78M 33.03M 10.46M 9.01M 30.13M
End period cash flow 21.62M 45.78M 33.03M 10.46M 9.01M
Total cash from operating activities -4.85M -27.05M -27.05M -21.77M -13.06M
Issuance of capital stock - 0.00M 0.00M 139.28M 0.00M
Depreciation 21.12M 19.08M 17.39M 13.10M 10.68M
Other cashflows from investing activities - -2.88M -2.11M -40.09M -8.56M
Change to inventory -8.47M -13.20M -26.28M -16.94M -5.05M
Change to account receivables -9.37M -4.75M -9.72M -3.98M -0.47M
Sale purchase of stock - - - 139.34M 0.14M
Other cashflows from financing activities 23.98M -3.41M -2.00M 27.83M 0.14M
Change to netincome - - - -20.67M 2.91M
Capital expenditures 11.11M 14.26M 18.98M 10.03M 16.01M
Change receivables - - - -3.98M -0.47M
Cash flows other operating - - - 2.34M -5.41M
Cash and cash equivalents changes - - - 0.84M -20.47M
Change in working capital -10.79M -22.93M -32.20M -17.76M -12.55M
Stock based compensation 17.78M 13.55M 10.53M 6.68M 5.84M
Other non cash items 6.84M 5.82M -0.62M -20.01M 0.35M
Free cash flow -15.96M -41.31M -46.03M -31.80M -29.07M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KIDS
Orthopediatrics Corp
0.20
0.64%
31.61 - - 2.40 1.77 2.62 48.54
ABT
Abbott Laboratories
-
-%
104.48 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-1.43
1.40%
100.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
0.19
0.06%
318.15 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-0.10
0.22%
47.50 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Orthopediatrics Corp

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

2850 Frontier Drive, Warsaw, IN, United States, 46582

574 268 6379

602

Name Title Year Born
Mr. Mark C. Throdahl Exec. Chairman 1951
Mr. David R. Bailey Pres, CEO & Director 1979
Mr. Fred L. Hite CFO, Principal Financial & Accounting Officer, COO and Director 1968
Mr. Daniel J. Gerritzen Exec. VP of Legal 1970
Mr. Gregory A. Odle Pres of Scoliosis 1970
Mr. Joseph W. Hauser Pres of Trauma & Deformity Correction 1982
Mr. Joel Batts Sr. VP of Clinical & Regulatory Affairs NA
Mr. Mark Karshner Sr. VP of International Sales NA
Mr. Gregory A. Odle President of Scoliosis 1970
Mr. Mark C. Throdahl Executive Chairman 1951

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…